Followers | 88 |
Posts | 3149 |
Boards Moderated | 0 |
Alias Born | 03/03/2010 |
Wednesday, June 18, 2014 1:55:56 PM
http://www.cnbc.com/id/101526282
I dunno if you can even trust this company they only have 1 Drug that is in Phase 2 This Drug is for a VERY Rare Disease 700 Million Dollar market cap for a Bio Tech With ONLY 1 Drug NO Revenues Losing Millions Book Value around 3.60$ a share trading at 17.50$ looks not only over priced and way over valued with only 1 Drug in the pipeline anything goes wrong and apprently they have had ALOT of Problems with this drug and currently their is NO Cure Company also states in its SEC Filings it could take YEARS for it to Develop any drug
http://www.cnbc.comInsmed's lung infection drug fails mid-stage study, shares fall
Wednesday, 26 Mar 2014 | 7:47 AM ET
Reuters
COMMENTSStart the Discussion
(Adds details, background; updates share movement)
March 26 (Reuters) - Insmed Inc said its only experimental drug failed to meet the main goal of a mid-stage trial on patients with a form of bacterial lung infection, sending shares down 34 percent in premarket trade.
The company said the inhaled antibiotic Arikayce did not reduce bacterial density, a measure of change in infection, significantly enough in patients with treatment-resistant nontuberculous mycobacterial(NTM) lung infections.
Insmed compared the drug, in combination with a standard treatment, with a combination of placebo and the standard treatment.
This is the second setback for the company which said in July last year that Arikayce, formerly known as Arikace, did not show better results than a competing drug made by Novartis AG in a late-stage study.
Insmed said on Wednesday patients treated with Arikayce experienced a greater number of adverse events, including throat irritation, than those on placebo.
The company, however, said the adverse events were consistent with those seen in patients receiving inhaled antibiotics.
NTM lung infections are caused by a type of bacteria found in soil as well as water. An infection can cause severe lung disease characterized by cough, fever and blood in the mucus.
Insmed's shares, which were halted prior to the announcement, fell to $12.00 in premarket trade. They closed at $18.30 on the Nasdaq on Tuesday.
/id/101526282
Recent INSM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 08:47:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 08:46:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/13/2024 08:28:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 11:49:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/10/2024 08:14:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 08:06:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/06/2024 08:19:01 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 09/06/2024 12:00:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 09/03/2024 09:22:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:10:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2024 07:57:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:28:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:26:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 08:05:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 08:01:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 09:30:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:00:26 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 11:00:05 AM
- Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update • PR Newswire (US) • 08/08/2024 11:00:00 AM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 08/02/2024 12:00:00 PM
- Insmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024 • PR Newswire (US) • 07/29/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2024 09:19:37 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 07/05/2024 12:00:00 PM
- Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference • PR Newswire (US) • 07/03/2024 01:03:00 PM
- Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025 • PR Newswire (US) • 06/27/2024 12:00:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM